Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s): AQSZF

Healthcare

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.

TSXV:AQS - Post by User

Aequus Pharmaceuticals Inc

Bullboard Posts

Post by Din051on Mar 03, 2017 11:20am

118 Views

Post# 25926916

Insider selling

Looks like some people on the inside sold because of they new that management were coming out with a .30 cent share offer, that's the only reason the stock went up to .48 cents and back down to .34. I hope regulators look into insider selling on non market information.

Bullboard Posts

Golden Minerals closes Yoquivo gold-silver project sale